A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 119
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SD
Long Form : spasmodic dysphonia
No. Year Title Co-occurring Abbreviation
2020 Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort. ADSD, BT, UVF
2019 A separation of innate and learned vocal behaviors defines the symptomatology of spasmodic dysphonia. ---
2019 An Appraisal of Printed Online Education Materials on Spasmodic Dysphonia. FKGL, FRE, HONcode, POEMs
2019 Atypical somatosensory-motor cortical response during vowel vocalization in spasmodic dysphonia. EEG
2019 Clinical experience with patients with spasmodic dysphonia and primary Meige syndrome. MS
2019 Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey. EMG
2019 Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients. ADSD, BoNT, URI
2019 Laboratory Evaluation of Spasmodic Dysphonia. AFP, ANA, TSH
2019 Laryngeal vibration as a non-invasive neuromodulation therapy for spasmodic dysphonia. VTS
10  2019 Outcome Measurement in the Treatment of Spasmodic Dysphonia: A Systematic Review of the Literature. ICF
11  2019 Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study. MS
12  2019 The extrinsic risk and its association with neural alterations in spasmodic dysphonia. ---
13  2019 The Impact of Socioeconomic Status on Voice Outcomes in Patients With Spasmodic Dysphonia Treated With Botulinum Toxin Injections. SES, VHI-10
14  2018 Anxiety and depression in spasmodic dysphonia patients. CAPE-V, DSSE, GSES, HADS, VHI-10
15  2018 Central voice production and pathophysiology of spasmodic dysphonia. ---
16  2018 Connectivity profiles of the insular network for speech control in healthy individuals and patients with spasmodic dysphonia. BA
17  2018 Polygenic Risk of Spasmodic Dysphonia is Associated With Vulnerable Sensorimotor Connectivity. ---
18  2018 Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study. SES
19  2018 The effect of unilateral thalamic deep brain stimulation on the vocal dysfunction in a patient with spasmodic dysphonia: interrogating cerebellar and pallidal neural circuits. BTX, DBS, ET, USDRS, Vim, VOA, VRQoL
20  2017 An open-label study of sodium oxybate in Spasmodic dysphonia. VT
21  2017 Brain Activity in Patients With Adductor Spasmodic Dysphonia Detected by Functional Magnetic Resonance Imaging. FC
22  2017 Communication-related affective, behavioral, and cognitive reactions in speakers with spasmodic dysphonia. BCL, MANOVA
23  2017 Neural correlates of dystonic tremor: a multimodal study of voice tremor in spasmodic dysphonia. DTv, MFG
24  2017 [Analysis of phonosurgical methods of treatment in spasmodic dysphonia]. TAM
25  2016 Behavior Assessment Battery: A Pilot Study of the Affective, Behavioral, and Cognitive Correlates Surrounding Spasmodic Dysphonia. ADSD, BAB
26  2016 Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia. BoNT, BoNT-A
27  2016 Cortical sensorimotor alterations classify clinical phenotype and putative genotype of spasmodic dysphonia. ---
28  2016 Factors Associated With Patient-perceived Hoarseness in Spasmodic Dysphonia Patients. CAPE-V, HADS, VHI-10
29  2016 Morell Mackenzie's Contribution to the Description of Spasmodic Dysphonia. ---
30  2016 Tracing Spasmodic Dysphonia: The Source of Ludwig Traube's Priority. ---
31  2015 Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education. ---
32  2015 Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients. BTX
33  2015 Impaired Limb Proprioception in Adults With Spasmodic Dysphonia. AI, UA
34  2015 Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin. ADSD, BTX, VHI, VL, VS
35  2015 The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients. AbSD, AdSD, BoNT-A, VT
36  2015 Type II thyroplasty changes cortical activation in patients with spasmodic dysphonia. SMA
37  2015 Value of Laryngeal Electromyography in Spasmodic Dysphonia Diagnosis and Therapy. BTX, EPs, LEMG, MUPs
38  2015 Voice Onset Time for the Word-Initial Voiceless Consonant /t/ in Japanese Spasmodic Dysphonia-A Comparison With Normal Controls. ABSD, ADSD, VOT
39  2014 Influence of consonant voicing characteristics on sentence production in abductor versus adductor spasmodic dysphonia. AB, AD
40  2014 Spasmodic dysphonia: let's look at that again. ADSD
41  2014 The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series. BTX
42  2014 The role of laryngoscopy in the diagnosis of spasmodic dysphonia. ---
43  2014 Treatment of spasmodic dysphonia with a neuromodulating electrical implant. AMNA, TA
44  2014 Validation of a telephone screening tool for spasmodic dysphonia and vocal fold tremor. ---
45  2014 Vocal outcome after endoscopic thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia. ASD, VHI
46  2014 Workplace productivity and voice disorders: a cognitive interviewing study on presenteeism in individuals with spasmodic dysphonia. SPS-6, WPAI-SHP
47  2013 Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia. BTX-A
48  2013 Disease-specific self-efficacy in spasmodic dysphonia patients. CAPE-V, HADS, SE, VHI-10
49  2013 Long-term Effect of Sodium Oxybate (Xyrem) in Spasmodic Dysphonia with Vocal Tremor. VT
50  2013 Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin. BTX, WPAI
51  2012 Abnormal structure-function relationship in spasmodic dysphonia. CT, GMV, IFG
52  2012 Case-control study of risk factors for spasmodic dysphonia: A comparison with other voice disorders. ---
53  2012 Coprevalence of anxiety and depression with spasmodic dysphonia: a case-control study. CI, OR
54  2012 Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin. ---
55  2011 Coprevalence of tremor with spasmodic dysphonia: a case-control study. ---
56  2011 Patient perceptions of factors leading to spasmodic dysphonia: a combined clinical experience of 350 patients. ---
57  2011 Risk and protective factors for spasmodic dysphonia: a case-control investigation. MCs
58  2011 Spasmodic dysphonia: a laryngeal control disorder specific to speech. ---
59  2011 Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. V-RQOL
60  2010 A pattern recognition approach to spasmodic dysphonia and muscle tension dysphonia automatic classification. MTD
61  2010 Abnormal activation of the primary somatosensory cortex in spasmodic dysphonia: an fMRI study. ABSD, ADSD
62  2010 Application of the Mandarin Chinese version of the Voice Handicap Index. UVFP, VHI
63  2010 Brainstem pathology in spasmodic dysphonia. ---
64  2009 Treatment of spasmodic dysphonia with homeopathic medicine: a clinical case report. ---
65  2008 Developing a scale of communicative participation: a cognitive interviewing study. ---
66  2008 Levels of Speech Usage: A Self-Report Scale for Describing How People Use Speech. ---
67  2008 Listening: the key to diagnosing spasmodic dysphonia. ABSD, ADSD
68  2007 Psychiatric comorbidity in patients with spasmodic dysphonia: a controlled study. VFP
69  2007 Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia. BTX-A
70  2007 The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients' experiences. ---
71  2006 Botulinum toxin injection and airflow stability in spasmodic dysphonia. BT, CV
72  2006 Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital. ---
73  2006 Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations. ---
74  2005 The consequences of spasmodic dysphonia on communication-related quality of life: a qualitative study of the insider's experiences. QOL
75  2004 Laryngeal electromyography in movement disorders: preliminary data. GTS, LEMG
76  2004 The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. BT
77  2003 Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience. ---
78  2003 Stuttering: a dynamic motor control disorder. PWS, TS
79  2002 [Results of using botulism toxin in the treatment of spasmodic dysphonia]. BTX
80  2001 Cortical dysfunction of the supplementary motor area in a spasmodic dysphonia patient. PET, SMA
81  2001 Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. OMD
82  2001 Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. VHI
83  2001 The syllable method: proportion of impaired syllables as an indicator of spasmodic dysphonia severity. ---
84  2001 Thyroplasty for adductor spasmodic dysphonia: further experiences. ---
85  2000 Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. BTX, SF-36, VHI
86  2000 Personality and voice disorders: a multitrait-multidisorder analysis. FD, MPQ, UVFP, VN
87  2000 Personality and voice disorders: a superfactor trait analysis. FD, UVFP, VN
88  2000 Personality traits and psychological factors in voice pathology: a foundation for future research. FD, VN
89  1999 Increased stability of airflow following botulinum toxin injection. COV, VT
90  1998 Botulinum toxin treatment for spasmodic dysphonia: percutaneous versus transoral approach. BT
91  1998 Direct measurement of subglottic pressure and laryngeal resistance in normal subjects and in spasmodic dysphonia. ---
92  1998 Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia. CGI, HARS, HDRS, SDS
93  1998 Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. ---
94  1998 Physiologic assessment of botulinum toxin effects in the rat larynx. BT, EMG
95  1998 Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction. ---
96  1998 The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia. ---
97  1998 [Adduction spastic dysphonia: clinical and treatment]. ---
98  1997 Adductor spasmodic dysphonia: case reports with acoustic analysis following botulinum toxin injection and acupuncture. ---
99  1997 Disfluency in spasmodic dysphonia: a multivariate analysis. VAS
100  1996 Laryngeal aerodynamic aspects of women with adductor spasmodic dysphonia. ---